MODIFIERS OF MYOCARDIAL INFARCTION ONSET
心肌梗死发作的调节因素
基本信息
- 批准号:2219855
- 负责人:
- 金额:$ 48.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1990
- 资助国家:美国
- 起止时间:1990-04-01 至 1997-11-30
- 项目状态:已结题
- 来源:
- 关键词:acute disease /disorder aspirin beta antiadrenergic agent cardiovascular disorder epidemiology cardiovascular disorder prevention case history chemoprevention circadian rhythms data collection methodology /evaluation diet disease /disorder proneness /risk exercise gender difference human subject interview myocardial infarction physiologic stressor psychological stressor questionnaires stress tobacco abuse
项目摘要
This is a revised competing renewal application to conduct a study
entitled Modifiers of Myocardial Infarction Onset (Modifiers Study) to
elucidate the pathophysiology of acute myocardial infarction (Ml)
onset. We will utilize the methodologic techniques, 50-hospital
national study group, and findings of the completed NHLBl-funded
Determinants of Myocardial Infarction Onset Study (Determinants Study).
The Modifiers Study will identify factors that increase or decrease the
susceptibility of patients to the triggers of acute Ml we have
previously identified.
The Determinants Study began in 1989, shortly after widespread
acceptance of the circadian variation in Ml occurrence. The study was
initiated to utilize state-of-the art epidemiologic techniques to
determine the role of daily activities in the triggering of Ml. The
investigators created a new epidemiologic technique (the case-crossover
method), developed and tested a 24-page interview form established a
large study group of hospitals with trained interviewers, instituted
quality control measures, and enrolled over 2,000 subjects. This
extensive activity has made the Determinants Study a centerpiece in the
developing field of research into triggering of acute disease onset.
The Determinants Study accomplished its four Specific Aims. It
demonstrated that awakening/activity, rather than the absolute time of
day, is responsible for morning triggering, that heavy exertion, anger,
and sexual activity are triggers of Ml with relative risks of 6, 3, and
2 respectively, that beta-blockade prevents triggering by
awakening/activity, and that a sedentary lifestyle markedly increases
the relative risk of triggering of Ml by heavy exertion.
The proposed Modifiers Study will answer the major questions raised by
the results of the Determinants Study. It will test hypotheses
concerning 5 groups of factors that are potential modifiers of
susceptibility to the triggering of acute MI: l) Pharmacologic means
of Prevention - that beta blockers, aspirin, angiotensin converting
enzyme inhibitors and estrogen use decrease susceptibility to triggers;
2) Timing - that susceptibility does not increase in the morning but
does in the winter, and that exogenous rather than endogenous daily
rhythms determine onset; 3) Traditional chronic risk factors - that
diabetes, hypertension, and smoking increase susceptibility and that
regular exercise decreases susceptibility (to triggers other than
exertion); 4) Gender - that women are less susceptible to triggering;
and 5) Dietary factors - that chronic moderate alcohol use and anti-
oxidants decrease susceptibility.
To test the above hypotheses, 5,700 interviews are needed. By the
completion of the Determinants Study in March 1993, over 2,000
interviews will be complete. Continuation in the Modifiers Study of
our current 77 interviews per month will provide the required 3,700
additional interviews by December 1997. To maintain the study
organization during the 8 month review of the Modifiers Study, we will
support nurse interviewing with limited non-federal funds.
The long-term goal of the proposed study is to identify more completely
the mechanisms by which triggering occurs, and thereby facilitate
identification of new means of prevention. Although most potential
triggering activities are unavoidable, triggering of acute Ml could be
prevented by using drugs or other interventions to sever the
physiologic link between potential triggers and their catastrophic
consequences.
这是一份经过修订的竞争性更新申请,用于进行研究
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES E MULLER其他文献
JAMES E MULLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES E MULLER', 18)}}的其他基金
DETERMINANTS OF THE ONSET OF MYOCARDIAL INFARCTION
心肌梗塞发病的决定因素
- 批准号:
3358467 - 财政年份:1990
- 资助金额:
$ 48.3万 - 项目类别:
DETERMINANTS OF THE ONSET OF MYOCARDIAL INFARCTION
心肌梗塞发病的决定因素
- 批准号:
3358468 - 财政年份:1990
- 资助金额:
$ 48.3万 - 项目类别:
DETERMINANTS OF THE ONSET OF MYOCARDIAL INFARCTION
心肌梗塞发病的决定因素
- 批准号:
3358466 - 财政年份:1990
- 资助金额:
$ 48.3万 - 项目类别:
TRIGGERS OF VENTRICULAR ARRHYTHMIAS (TOVA) STUDY
室性心律失常 (TOVA) 触发因素研究
- 批准号:
6182326 - 财政年份:1990
- 资助金额:
$ 48.3万 - 项目类别:
TRIGGERS OF VENTRICULAR ARRHYTHMIAS (TOVA) STUDY
室性心律失常 (TOVA) 触发因素研究
- 批准号:
6389071 - 财政年份:1990
- 资助金额:
$ 48.3万 - 项目类别:
TRIGGERS OF VENTRICULAR ARRHYTHMIAS (TOVA) STUDY
室性心律失常 (TOVA) 触发因素研究
- 批准号:
2849665 - 财政年份:1990
- 资助金额:
$ 48.3万 - 项目类别:
DETERMINANTS OF THE ONSET OF MYOCARDIAL INFARCTION
心肌梗塞发病的决定因素
- 批准号:
3358469 - 财政年份:1990
- 资助金额:
$ 48.3万 - 项目类别:
相似国自然基金
Aspirin调控AKT/Foxo3a/BIM通路延缓吡咯替尼耐药作用机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:0.0 万元
- 项目类别:省市级项目
Aspirin与自噬通路及核转录因子FoxG1在听觉系统退行性变中的协同调控机制研究
- 批准号:81800915
- 批准年份:2018
- 资助金额:21.0 万元
- 项目类别:青年科学基金项目
Aspirin联合牙周膜干细胞再生全脱位牙牙周组织机制研究
- 批准号:81760190
- 批准年份:2017
- 资助金额:32.0 万元
- 项目类别:地区科学基金项目
可注射温敏型水凝胶缓释Aspirin碳点和EPO促牙周组织再生的研究
- 批准号:81600879
- 批准年份:2016
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
Aspirin协同IFN-α抑制肝癌转移复发的作用及机制研究
- 批准号:30972889
- 批准年份:2009
- 资助金额:31.0 万元
- 项目类别:面上项目
胃癌microRNA特异表达与靶基因调控及Aspirin的作用
- 批准号:30873099
- 批准年份:2008
- 资助金额:35.0 万元
- 项目类别:面上项目
相似海外基金
Postpartum low-dose aspirin to augment vascular recovery following a hypertensive disorder of pregnancy
产后小剂量阿司匹林可促进妊娠高血压疾病后的血管恢复
- 批准号:
10644089 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Aspirin, Lp(a) and Primary Prevention of Cardiovascular Events
阿司匹林、Lp(a) 和心血管事件的一级预防
- 批准号:
10720757 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Early Double Low-Dose Aspirin to Reduce Preeclampsia and Miscarriage: a Global Approach RCT
早期双倍低剂量阿司匹林减少先兆子痫和流产:全球方法随机对照试验
- 批准号:
10711793 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Aspirin for Primary Prevention of Cardiovascular Disease in Patients with Elevated Lipoprotein(a)
阿司匹林用于脂蛋白升高患者心血管疾病的一级预防(a)
- 批准号:
10739016 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
The PARTUM (Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity) Trial
PARTUM(产后阿司匹林减少血栓栓塞过度发病率)试验
- 批准号:
498295 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Operating Grants
Health Outcomes of Discontinuing Aspirin in Older Adults with Alzheimer's Disease and Related Dementias
患有阿尔茨海默病和相关痴呆症的老年人停用阿司匹林的健康结果
- 批准号:
10662129 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
A study on the use of aspirin mini tablets for children with Kawasaki disease for the practical application of mini tablets
阿司匹林迷你片在川崎病患儿中的应用研究
- 批准号:
23K16462 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Is Aspirin a Cost-Effective Thromboprophylaxis Alternative for Orthopaedic Trauma Patients?
阿司匹林是骨科创伤患者经济有效的血栓预防替代方案吗?
- 批准号:
10784156 - 财政年份:2023
- 资助金额:
$ 48.3万 - 项目类别:
Aspirin and severe maternal morbidity and mortality and adverse pregnancy outcomes
阿司匹林与严重孕产妇发病率和死亡率以及不良妊娠结局
- 批准号:
469014 - 财政年份:2022
- 资助金额:
$ 48.3万 - 项目类别:
Operating Grants
Effects of inflammaging on intestinal epithelial cells and aspirin chemoprevention.
炎症对肠上皮细胞的影响和阿司匹林化学预防。
- 批准号:
10152090 - 财政年份:2021
- 资助金额:
$ 48.3万 - 项目类别: